Shares of Viking Therapeutics (VKTX) have more than tripled in market value in the past year. The upside was triggered by positive updates on its pipeline programs for obesity and non-alcoholic steatohepatitis (NASH) indications. Based on the encouraging results, management intends to meet with the FDA to discuss the late-stage study design and timings for both programs. In the past year, the stock has significantly outperformed the industry's 2.5% decline. The stock has outperformed the sector and the S&P ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX) . Viking Therapeutics currently ...

The new drugs this company is developing could be worth a lot more than the present market value of its stock. Shares of Viking Therapeutics (VKTX 0.43%), a clinical-stage drugmaker working on metabolic treatments, have tripled in value this year. Despite the huge run-up, analysts who follow the company think it has heaps more upside. The average analyst who follows Viking Therapeutics thinks it can rise to $113.55 per share. Reaching the consensus expectation would result in a gain of about 76% from the st ...

Shares of Viking Therapeutics (VKTX) have soared nearly 25% in the past month, all thanks to progress with its investigational obesity and non-alcoholic steatohepatitis (NASH) candidates, which management plans to advance to late-stage development by early 2025. Last month, alongside its second-quarter earnings results, VKTX reported that it had received feedback from the FDA regarding the next steps in the developmental pathway for the obesity drug VK2735. Based on such feedback, the company is gearing up ...

One preliminary piece of evidence is sending its shares higher. Viking Therapeutics (VKTX 2.01%) just gave shareholders a few more reasons to be excited for the future. With its shares soaring by a stunning 34% on July 25 thanks to second-quarter earnings, the bull thesis for its continued outperformance is stronger than ever. It's clear now that the biotech has what it'll need to take on powerful competitors like Eli Lilly and Novo Nordisk. Here's why. Strong clinical data and minimal expenditures make a v ...

All of this has pushed shares of Viking to major gains this year, with performance even surpassing that of AI powerhouse Nvidia. Viking is developing injectable and oral GIP and GLP-1 receptor agonists, treatments that act on hormones controlling blood sugar levels and appetite. Just last week, the company said it's advancing VK-2735, its injectable candidate, into a phase 3 trial and has scheduled an end-of-phase 2 meeting with the U.S. Food and Drug Administration for later this year. In the phase 2 trial ...

Among the hottest investments these days are pharma and biotech companies that make weight loss drugs. Demand for these products surpasses supply, and analysts predict that sales growth for the new classes of effective treatments is just getting started. According to a forecast by Goldman Sachs Research, the global weight loss drug market may multiply by a factor of 16 to reach $100 billion by the end of the decade. Unlike Eli Lilly and Novo Nordisk, Viking is a clinical-stage company. It doesn't have any p ...

Viking Therapeutics Today VKTX Viking Therapeutics $69.04 +18.63 (+36.96%) 52-Week Range $8.28 ▼ $99.41 Price Target $111.56 Add to Watchlist Viking Therapeutics NASDAQ: VKTX is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics' earnings report for the second quarter of 2024 was impressive, capturing the attention of investors and the Viking Therapeutics' analyst community. Following the release of its ear ...

The clinical-stage biopharmaceutical company should soon be closer to potentially launching its first product. This weight loss was better than the amount achieved by Eli Lilly's Zepbound and Novo Nordisk's Wegovy in clinical trials. With VK2735 advancing into late-stage testing, investors know that Viking will be closer to potentially launching what could be a blockbuster drug. Risk-averse investors should probably stay on the sidelines with Viking. However, I think the biotech stock is a great pick for ag ...

It brings the San Diego-based company one step closer to joining the highly popular market for GLP-1s, which analysts say could grow into a $150 billion market by the end of the decade. Shares of both Novo Nordisk and Eli Lilly fell around 2% in premarket trading Thursday. But after receiving written feedback from the Food and Drug Administration, the company has decided to move the injection directly into a phase three trial, CEO Brian Lian said during an earnings call on Wednesday. That decision will like ...